Subchondral Bone Sclerosis: Causes, Symptoms & Treatment

Subchondral bone sclerosis is a thickening and hardening of the bone layer that sits just beneath your joint cartilage, and it develops primarily as a response to abnormal or excessive mechanical stress on a joint. It is closely linked to osteoarthritis, where it is considered one of the hallmark features alongside cartilage breakdown and bone spur formation. Though the condition itself is often discovered incidentally on an X-ray, the stiff, remodeled bone it produces can contribute to joint pain, reduced shock absorption, and accelerating damage to the cartilage above it.

What Subchondral Bone Actually Does

The word “subchondral” just means “below the cartilage.” In a healthy joint, a thin plate of bone sits directly beneath the smooth articular cartilage that caps the ends of your bones. Below that plate is a network of spongy trabecular bone, rich in blood vessels and marrow. Together, this subchondral layer acts as a shock absorber: when you walk, run, or climb stairs, it deforms slightly to distribute the load across the joint surface. Healthy cartilage and healthy subchondral bone work in tandem. The cartilage handles compression and provides a near-frictionless gliding surface, while the bone underneath cushions impact and supplies nutrients to the deepest layers of cartilage through diffusion.

When this system goes wrong, both tissues suffer. Subchondral bone sclerosis refers specifically to the bone side of the problem: the trabecular network fills in, the subchondral plate gets thicker, and the bone as a whole becomes denser on imaging. Counterintuitively, denser does not mean stronger in this context. The remodeled bone is stiffer but less elastic, meaning it absorbs shock poorly and transmits more force directly into the cartilage above.

How Mechanical Overload Drives Sclerosis

The primary trigger for subchondral sclerosis is persistent abnormal mechanical stress. When forces through a joint are uneven or excessive, the subchondral bone responds with accelerated remodeling. Microfractures form in the bone and at the junction between bone and cartilage, and the body’s repair response produces new bone tissue faster than it can mature properly. Over time, the trabecular spaces fill in and the subchondral plate thickens.¹ This is not a one-time injury event. It is a chronic cycle: abnormal loading causes microdamage, the bone repairs with denser tissue, that stiffer bone shifts more stress onto surrounding structures, and the cycle repeats.

Research in animal models has shown that mechanical overload activates specific cellular pathways in bone-forming cells (osteoblasts), promoting their differentiation and driving them to lay down new bone. One recent mouse study demonstrated that overloaded osteoblasts produced subchondral sclerosis through a signaling chain involving a mechanical sensor called Piezo1, which opens calcium channels in the cell and triggers downstream bone formation.² The same research found that excessive stress leads to uneven settlement of the tibial plateau, the flat top of the shinbone. That collapse changes the geometry of the knee and worsens the force imbalance that started the problem.

Disrupted loading does not always mean excessive loading. Abnormal gait patterns after a ligament tear, joint instability, obesity, malalignment of the leg, and even prolonged immobilization followed by a return to activity can all create the kind of uneven stress that promotes sclerosis. In preclinical studies, appropriate loading appears to protect against subchondral damage, while both overloading and underloading accelerate it.³

The Connection to Osteoarthritis

Subchondral bone sclerosis and osteoarthritis are so closely intertwined that sclerosis is considered a hallmark of the disease, alongside progressive cartilage loss.⁴ What remains debated is which comes first. For decades, osteoarthritis was viewed as purely a cartilage disease, with subchondral changes treated as a secondary consequence. More recent work has challenged that framing. Some researchers now argue that changes in subchondral bone can precede visible cartilage damage and may even initiate it, because stiffened bone shifts mechanical forces upward into vulnerable cartilage.

One of the more surprising findings in this area is that sclerotic subchondral bone, despite looking dense on X-rays, is actually undermineralized compared to healthy bone. Studies examining tissue from osteoarthritic joints have found a thicker subchondral plate and volumetrically denser trabecular bone, but with lower mineral content than normal.⁵ In other words, the bone is building faster than it can properly mineralize. It looks thick and strong on an X-ray, but its material properties are actually inferior. This helps explain why sclerotic bone is stiffer yet more brittle, and why it fails as a shock absorber.

What makes the cartilage-bone relationship especially destructive is the crosstalk between tissues. When subchondral bone remodels, new blood vessels grow from the bone into the deepest layer of cartilage, penetrating tissue that is normally avascular. Sensory nerves follow those blood vessels, driven by shared growth factors.⁶ This nerve ingrowth is thought to be a major contributor to osteoarthritis pain, because it brings pain-sensing fibers into areas that were previously free of them.

The Role of Metabolic Factors

Mechanical overload is not the only cause. Metabolic conditions, particularly obesity and metabolic syndrome, independently predispose joints to subchondral sclerosis. Research in an obese rat model found that animals with metabolic syndrome developed increased subchondral trabecular bone volume and decreased bone porosity, essentially sclerosis, at all ages studied, along with elevated levels of an inflammatory marker in the blood.⁷ This suggests that systemic inflammation can drive subchondral remodeling even beyond what the extra body weight alone would cause through increased joint loading.

This metabolic angle matters because it widens the population at risk. A person with a healthy body weight but insulin resistance and chronic low-grade inflammation may still be vulnerable to subchondral changes in their joints. And for someone who is both overweight and metabolically unhealthy, the combination of excessive mechanical stress and circulating inflammatory signals creates a double hit on subchondral bone.

Symptoms and How Sclerosis Causes Pain

Subchondral bone sclerosis itself does not always cause symptoms. Plenty of people have sclerotic changes visible on imaging without ever knowing it. When symptoms do occur, they typically present as joint pain that worsens with activity, stiffness after periods of rest, and a gradually decreasing range of motion. The affected joint may feel achy during or after weight-bearing and may sometimes swell. Because sclerosis rarely occurs in isolation, these symptoms blend with those of the underlying osteoarthritis.

The thickened, stiffened bone changes the mechanical environment of the joint. As shock absorption decreases, the cartilage absorbs more impact, accelerating its own breakdown.⁸ The trabecular network fills in, the bone becomes stiffer with less elasticity, and the result is a joint surface that jars rather than cushions. This can create a sensation of grinding or crunching (crepitus) in advanced cases.

Pain specifically attributable to the subchondral bone may come from several sources. Bone marrow lesions, areas of edema and microdamage within the subchondral region that show up as bright spots on MRI, are strongly correlated with reported knee pain. More directly, the nerve ingrowth described earlier means that sensory fibers are now present in tissues where they do not normally belong. These nociceptors can become sensitized in the inflammatory environment of an osteoarthritic joint, producing pain signals in response to normal mechanical loads.⁹

How It Is Diagnosed

Subchondral sclerosis is usually spotted first on a plain X-ray, where it appears as a band of increased whiteness (density) along the joint surface. Radiologists look for thickening of the subchondral plate, narrowing of the joint space, and the presence of osteophytes (bone spurs) as part of the overall osteoarthritis picture. X-ray is inexpensive and widely available, which makes it the standard first step, but it only shows you the density of the bone. It cannot reveal what is happening inside the marrow or in the overlying cartilage.

MRI provides a more detailed picture. On MRI, subchondral sclerosis typically appears as a low-signal band on most standard sequences, reflecting the dense fibrous tissue and thickened trabeculae that replace normal fatty marrow.¹⁰ MRI also picks up bone marrow lesions, sometimes called bone marrow edema-like lesions, which are a related but distinct finding. These lesions are strongly associated with the later development of subchondral cysts in the same region, and their presence often predicts where cartilage loss will progress.¹¹

CT scanning, while less commonly used for routine osteoarthritis workup, can quantify sclerosis more precisely by measuring bone density in Hounsfield units. A recent study of ankle osteoarthritis used CT-derived density ratios of the subchondral bone to assess sclerosis severity and correlate it with patient-reported pain scores.¹² This kind of quantitative imaging is primarily a research tool for now, but it hints at where diagnostic precision may be heading.

Exercise, Loading, and Conservative Management

Given that both overloading and underloading harm subchondral bone, the question of how much to move an affected joint is critical. The evidence suggests that low-intensity exercise is protective, while high-intensity exercise can accelerate joint degeneration. After an ACL injury, for instance, animal studies have found that brief joint unloading reduces bone spur formation and cartilage damage, but prolonged immobilization causes muscle wasting and cartilage degradation. Once activity resumes, the intensity matters: gentle exercise helps, and aggressive exercise hurts.¹³

For the knees, unloader braces and wedged insoles aim to shift mechanical stress away from the more damaged compartment. The goal is to reduce articular contact stress in the region where sclerosis and cartilage loss are concentrated.¹⁴ These devices do not reverse existing sclerosis, but they address the mechanical overload that drives progression. Weight management works on a similar principle: reducing the load on the joint surface means less microdamage and slower bone remodeling.

Physical therapy programs that focus on strengthening the muscles around the joint, improving proprioception, and restoring normal movement patterns are a standard part of management. Strong quadriceps, hamstrings, and hip stabilizers absorb forces that would otherwise pass through the joint surfaces. Aquatic exercise is often recommended because the buoyancy of water reduces joint loading while still allowing meaningful muscle work.

Medications That Target Bone Remodeling

If subchondral sclerosis is driven by excessive bone remodeling, drugs that slow bone turnover seem like an obvious solution. Bisphosphonates, the most widely used medications for osteoporosis, work by inhibiting osteoclasts, the cells that break down bone. Because osteoclast activity is part of the remodeling cycle that leads to sclerosis, there has been interest in whether bisphosphonates could slow subchondral changes in osteoarthritis.¹⁵

The results have been disappointing. A propensity-matched cohort study using data from the Osteoarthritis Initiative found no significant differences in subchondral bone measures, including bone volume fraction, trabecular number, trabecular thickness, and bone mineral density, between people taking bisphosphonates and those who were not.¹⁶ Importantly, the study also found that bisphosphonates did not worsen sclerosis either. The bottom line is that simply shutting down bone resorption does not appear to fix the underlying problem in osteoarthritis, and some researchers argue this is because the remodeling in OA is qualitatively different from the bone loss in osteoporosis.

Other pharmacological approaches remain largely experimental. Some preclinical work has shown that suppressing bone resorption can have secondary positive effects on cartilage health, while increasing resorption worsens it.¹⁷ This suggests the bone-cartilage axis is a legitimate target, even if the right drug has not been found yet. Researchers are actively developing disease-modifying osteoarthritis drugs (DMOADs) aimed at signaling pathways that control subchondral bone turnover.¹⁸ None have reached widespread clinical use so far, but the pipeline reflects a real shift in thinking: treating osteoarthritis as a whole-joint disease rather than a cartilage-only problem.

Subchondroplasty and Interventional Procedures

When bone marrow lesions are contributing to pain, some surgeons have turned to subchondroplasty, a minimally invasive procedure in which calcium phosphate bone substitute is injected directly into the damaged subchondral bone under fluoroscopic guidance.¹⁹ The idea is to provide structural support and a scaffold for the body’s own repair, filling in areas where the bone has become edematous and weakened. Some early case series reported pain relief, and the technique has been marketed as a joint-preservation option for patients trying to delay knee replacement.²⁰

The evidence, however, is mixed at best. A study of patients with advanced osteoarthritis and symptomatic bone marrow lesions found that percutaneous calcium phosphate injection yielded poor results in a concerning proportion of patients. The researchers concluded that they would advise against the procedure in patients with advanced osteoarthritic changes.²¹ The lesson seems to be one of timing and patient selection: injecting bone substitute into a joint that is already severely degenerated does not meaningfully change the trajectory. Whether it helps earlier in the disease course remains an open question without strong evidence yet.

Surgical Approaches for Advanced Disease

When conservative measures and less invasive procedures fail, surgery becomes the conversation. For medial compartment osteoarthritis with associated subchondral sclerosis, high tibial osteotomy (HTO) is a joint-preserving option. The surgeon cuts and realigns the upper shinbone to shift load away from the damaged medial compartment and onto the healthier lateral side. This directly addresses the mechanical overload driving sclerosis. A randomized trial comparing HTO to knee joint distraction (a technique where the joint surfaces are temporarily separated using an external fixator) found that both approaches led to increases in joint space width at one year, suggesting some structural recovery was possible.²²

For focal osteochondral defects, where both the cartilage and underlying bone are damaged in a specific area, osteochondral scaffolds and transplantation procedures aim to restore both layers simultaneously. The recognition that subchondral bone status matters to cartilage repair outcomes has pushed surgical thinking beyond surface-only cartilage procedures. If the bone beneath a cartilage repair is sclerotic and poorly vascularized, the repair tissue struggles to integrate and survive long-term.²³

Total joint replacement remains the definitive treatment when the joint is severely destroyed. During arthroplasty, the sclerotic bone is resected along with the remaining cartilage, and both surfaces are replaced with metal and polyethylene components. By the time sclerosis is advanced enough to warrant replacement, the conversation has usually moved past the subchondral bone specifically and into overall joint function, pain management, and quality of life.

Cellular Pathways Behind Abnormal Bone Formation

Researchers trying to develop targeted therapies have zeroed in on several signaling pathways that control how osteoblasts behave in the subchondral region. The Wnt/β-catenin pathway has received particular attention. In osteoarthritic subchondral bone, β-catenin levels appear to rise as the disease progresses from mild to moderate stages, promoting excessive osteoblast activity and bone formation. A counterbalancing protein called DKK3 decreases during the same progression, removing a natural brake on the pathway.²⁴

In mouse models, a plant-derived compound called cardamonin was shown to inhibit osteoblast differentiation by downregulating Wnt/β-catenin signaling, and this reduced subchondral sclerosis.²⁵ These are early-stage findings in animals, not treatment recommendations, but they illustrate the principle: if you can dial down the overactive bone-forming pathways without shutting off normal maintenance, you may be able to slow the sclerotic process. Several other molecular targets are under investigation, and the broader push toward disease-modifying drugs for osteoarthritis is increasingly treating the subchondral bone as a central rather than peripheral player in the disease.

Bone Marrow Lesions and Subchondral Cysts

Two findings frequently accompany subchondral sclerosis on imaging and are worth understanding separately, because they often drive treatment decisions. Bone marrow lesions (sometimes called bone marrow edema-like lesions) appear as bright areas on fluid-sensitive MRI sequences and represent zones of microdamage, fibrosis, and inflammation within the subchondral bone. They are strongly associated with pain and predict where further joint damage will occur.

Subchondral cysts, which appear as fluid-filled or fibrous voids within the bone, tend to develop in areas where bone marrow lesions already exist. In the MOST study, a large longitudinal cohort of people with or at risk for knee osteoarthritis, the presence of a bone marrow lesion in a given subregion was associated with roughly 13 times the odds of developing a subchondral cyst in that same location, even after accounting for cartilage loss.¹¹ This suggests a progression: abnormal stress causes microdamage, bone marrow lesions form, and if the process continues, cysts develop. Sclerosis, lesions, and cysts often coexist and reinforce one another, creating a deteriorating environment for whatever cartilage remains overhead.

For patients who see these terms on their MRI report, the practical implication is that bone marrow lesions are more than cosmetic findings. They represent active disease and deserve attention, whether through load modification, physical therapy, pharmacological treatment, or in some cases procedural intervention. The MRI sequence used also matters for accurate assessment. Different MRI sequences depict bone marrow lesions at different sizes, and the sequence choice can affect both diagnosis and research outcomes.²⁶